Search Results
Jul 22, 2026, 07:00 ET Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
pipeline.The Private Placement is expected to close immediately prior to the completion of Mentari's merger with InMed Pharmaceuticals, Inc. (Nasdaq: INM) (the "Merger") and concurrently with the previously announced $290 million private placement (the "Initial Private Placement"). The combined company
More news about: Mentari Therapeutics
Jul 06, 2026, 19:15 ET Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-esi-inm-hun-oln-obtaining-fair-deals-for-their-shareholders-302818806.htmlSOURCE
More news about: Halper Sadeh LLP
Jul 06, 2026, 14:18 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--NIMU, INM, OLN, and HUN
INM) related to its merger with Mentari Therapeutics, Inc. Upon closing of the proposed transaction, InMed shareholders are expected to own approximately
More news about: Monteverde & Associates PC
Jun 12, 2026, 11:51 ET Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-gbtg-inm-czr-tmhc-obtaining-fair-deals-for-their-shareholders-302799124.htmlSOURCE
More news about: Halper Sadeh LLP
May 28, 2026, 18:57 ET Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-ramp-inm-d-nee-obtaining-fair-deals-for-their-shareholders-302785004.htmlSOURCE
More news about: Halper Sadeh LLP
May 28, 2026, 14:40 ET SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM
INM) related to its merger with Mentari Therapeutics, Inc. Upon closing of the proposed transaction, InMed shareholders are expected to own approximately
More news about: Monteverde & Associates PC
May 20, 2026, 10:34 ET /C O R R E C T I O N -- InMed Pharmaceuticals/
VANCOUVER, BC and SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is pleased to announce that it has entered into a definitive merger agreement (the "Agreement") for an all-stock transaction
More news about: InMed Pharmaceuticals